Subcutaneous (SC) : Common sites include the upper arm, thigh, or abdomen
In fact, even when development as a prescription obesity drug slowed (after some longer trials showed only modest results), AOD-9604 found new life as a wellness peptide due to its excellent safety profile
Nonparametric estimation of the number of classes in a population
Daily intraperitoneal administration for 11 days reduced body weight gain, decreased white adipose tissue mass by approximately 35%, and reduced adipocyte size, while food intake between treated and control groups did not differ significantly
For more, see our AMINO-1MQ research guide
Factors affecting individual response Response to AHK-Cu varies substantially between individuals